References
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
- Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011;117:936–941.
- Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Ballen KK, Becker PS, Emmons RBV, et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 2002;100:442–450.
- Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–828.
- Peniket AJ, Ruiz De Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667–678.
- Pörtner LM, Schönberg K, Hejazi M, et al. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16. Cancer Immunol Immunother 2012;61:1869–1875.
- Guo M, Hu K-X, Liu G-X, et al. HLA-mismatched stem-cell microtransplantation [as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol 2012;30:4084–4090.
- Colvin GA, Berz D, Ramanathan M, et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 2009;15:421–431.
- Dey BR, McAfee S, Colby C, et al. Anti-tumor response despite loss of donor chimerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005;128:351–359.
- Zarling J, Kay N, Grant B, et al. Human anti-lymphoma responses generated in vitro and in vivo following sensitization by allogeneic leukocytes. Cancer Immunol Immunother 1983;5:237–239.
- Thomas DA, O’Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104:1624–1630.